Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Cemsidomide · CFT-7455

Small molecule (Molecular glue degrader) · Degrader of Cereblon (CRBN) (CRBN) · developed by C4 Therapeutics

Phase 2 Most advanced trial
1 Registered trials

What is Cemsidomide?

Cemsidomide is an orally bioavailable modulator that binds cereblon, the substrate receptor of the CRL4-CRBN E3 ubiquitin ligase, redirecting it to ubiquitinate and degrade the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). It is being studied in multiple myeloma, including relapsed or refractory disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CFT-7455
Drug type
Small molecule (Molecular glue degrader)
Targets
Cereblon (CRBN) (CRBN), Ikaros (IKZF1) (binding partner it blocks), Aiolos (IKZF3) (binding partner it blocks)
Mechanism
Degrader of Cereblon (CRBN) (CRBN)
Pathways
CRL4-CRBN E3 ubiquitin ligase-mediated ubiquitination, proteasome-mediated degradation of transcription factors, T-lymphocyte activation
Therapy area
Oncology
Developer
C4 Therapeutics, Inc.
In trials of
CCCC
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
D86MF5H9WJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07284758 Phase 2 Multiple Myeloma Recruiting CCCC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple MyelomaRelapsed/Refractory Multiple Myeloma

Other drugs acting on CRBN

Mezigdomide Phase 3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.